ESR1 and breast carcinoma: In contrast to our results, it was found that in ER+ breast cancer a low estrogen response score tumor was significantly infiltrated with both anti- and pro-cancer immune cells, as well as B cells, including CD8+ T cells, CD4+ T cells, M1 macrophages, dendritic cells, regulatory T cells, Th2 cells, M2 macrophages, and plasma cells, and associated with enhanced cytolytic activity score [41].